Disulfide cross-linked micelles of novel HDAC inhibitor thailandepsin A for the treatment of breast cancer.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Biomaterials

• Publication date

  2015-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.biomaterials.2015.07.033PMID 26218744PMCID PMC4550558
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

  2015cited by this paper
• The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth.

  2014cited by this paper
• Stimuli-responsive cross-linked micelles for on-demand drug delivery against cancers.

  2014cited by this paper
• Oxidative stress-induced cyclin D1 depletion and its role in cell cycle processing.

  2013cited by this paper
• An NQO1-Initiated and p53-Independent Apoptotic Pathway Determines the Anti-Tumor Effect of Tanshinone IIA against Non-Small Cell Lung Cancer

  2012cited by this paper
• Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy

  2012cited by this paper
• CIP2A is a target of bortezomib in human triple negative breast cancer cells

  2012cited by this paper
• "OA02" peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo.

  2012cited by this paper
• Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell lymphoma.

  2012cited by this paper
• Well-defined, reversible disulfide cross-linked micelles for on-demand paclitaxel delivery.

  2011cited by this paper
• The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles.

  2011cited by this paper
• Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung.

  2011cited by this paper
• Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma

  2011cited by this paper
• Thailandepsins: bacterial products with potent histone deacetylase inhibitory activities and broad-spectrum antiproliferative activities.

  2011cited by this paper
• Vorinostat Induces Reactive Oxygen Species and DNA Damage in Acute Myeloid Leukemia Cells

  2011cited by this paper
• PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma.

  2011cited by this paper
• Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.

  2010cited by this paper
• Global Patterns of Cancer Incidence and Mortality Rates and Trends

  2010cited by this paper
• The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.

  2010cited by this paper
• Reconstitution of the FK228 Biosynthetic Pathway Reveals Cross Talk between Modular Polyketide Synthases and Fatty Acid Synthase

  2010cited by this paper
• Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect

  2010cited by this paper
• PCI-24781 Induces Caspase and Reactive Oxygen Species–Dependent Apoptosis Through NF-κB Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells

  2009cited by this paper
• A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer.

  2009cited by this paper
• Genetic dissection of histone deacetylase requirement in tumor cells

  2009cited by this paper
• Reversibly stabilized multifunctional dextran nanoparticles efficiently deliver doxorubicin into the nuclei of cancer cells.

  2009cited by this paper
• Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis.

  2008cited by this paper
• Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

  2008cited by this paper
• Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade

  2008cited by this paper
• Disulfide-cross-linked PEG-poly(amino acid)s copolymer micelles for glutathione-mediated intracellular drug delivery.

  2008cited by this paper
• Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo

  2008cited by this paper
• A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.

  2008cited by this paper
• Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study

  2008cited by this paper
• Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).

  2007cited by this paper
• Clinical Significance of Histone Deacetylase 1 Expression in Patients with Hepatocellular Carcinoma

  2007cited by this paper
• The histone deacetylase inhibitor, PXD101, potentiates bortezomib‐induced anti‐multiple myeloma effect by induction of oxidative stress and DNA damage

  2007cited by this paper
• Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits.

  2006cited by this paper
• The proteasome and proteasome inhibitors in cancer therapy.

  2006cited by this paper
• Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells

  2006cited by this paper
• Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast*

  2005cited by this paper
• Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis

  2005cited by this paper
• Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression.

  2004cited by this paper
• Targeting the ubiquitin-proteasome pathway in breast cancer.

  2004cited by this paper
• Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A.

  1999cited by this paper
• Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway

  1999cited by this paper
• Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery.

  1997cited by this paper
• Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt.

  1997cited by this paper
• A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

  1986cited by this paper
• Edinburgh Research Explorer Differential expression of selected histone modifier genes in human solid cancers

  year unknowncited by this paper

• Improving the Thrombocytopenia Adverse Reaction of Belinostat Using Human Serum Albumin Nanoparticles

  2024cites this paper
• Perspectives on materials: Reality and potential of epigenetic drug nano-delivery

  2024cites this paper
• Disulfide bonds as a molecular switch of enzyme-activatable anticancer drug precise release for fluorescence imaging and enhancing tumor therapy.

  2024cites this paper
• Epigenetic Drug Interventions in Breast Cancer: A Narrative Review of Current Research and Future Directions

  2024cites this paper
• Administration of inhibitory molecules through nanoparticles in breast cancer therapy.

  2023cites this paper
• HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma

  2023cites this paper
• Advances in the Delivery and Development of Epigenetic Therapeutics for the Treatment of Cancer.

  2023cites this paper
• Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival.

  2023cites this paper
• HDAC-an important target for improving tumor radiotherapy resistance

  2023cites this paper
• Programmed-response cross-linked nanocarrier for multidrug-resistant ovarian cancer treatment.

  2023cites this paper
• Breast tumor‐targeted drug delivery via polymer nanocarriers: Endogenous and exogenous strategies

  2023cites this paper
• Stimuli‐responsive crosslinked nanomedicine for cancer treatment

  2022cites this paper
• Suberoylanilide hydroxamic acid (SAHA) inhibits transforming growth factor-beta 2-induced increases in aqueous humor outflow resistance

  2021cites this paper
• Hybrid artificial cell-mediated epigenetic inhibition in metastatic lung cancer.

  2021cites this paper
• LHRH‐Targeted Redox‐Responsive Crosslinked Micelles Impart Selective Drug Delivery and Effective Chemotherapy in Triple‐Negative Breast Cancer

  2020cites this paper
• Two-way magnetic resonance tuning and enhanced subtraction imaging for non-invasive and quantitative biological imaging

  2020cites this paper
• Recent advances on small-molecule nanomedicines for cancer treatment.

  2019cites this paper
• The ROMP: A Powerful Approach to Synthesize Novel pH-Sensitive Nanoparticles for Tumor Therapy

  2019cites this paper
• Pulmonary Carcinoid Surface Receptor Modulation Using Histone Deacetylase Inhibitors

  2019cites this paper
• Solanesol Derived Therapeutic Carriers for Anticancer Drug Delivery.

  2019cites this paper
• Effect of Histone Deacetylase Inhibition on Ovarian Cancer Cell Survival

  2019cites this paper
• Reversibly disulfide cross-linked micelles improve the pharmacokinetics and facilitate the targeted, on-demand delivery of doxorubicin in the treatment of B-cell lymphoma.

  2018cites this paper
• Interaction of spin-labeled HPMA-based nanoparticles with human blood plasma proteins - the introduction of protein-corona-free polymer nanomedicine.

  2018cites this paper
• Novel Redox‐Responsive Polymeric Magnetosomes with Tunable Magnetic Resonance Property for In Vivo Drug Release Visualization and Dual‐Modal Cancer Therapy

  2018cites this paper
• Natural Products and Chemical Biology Tools: Alternatives to Target Epigenetic Mechanisms in Cancers.

  2018cites this paper
• The Detailed Comparison of Cell Death Detected by Annexin V-PI Counterstain Using Fluorescence Microscope, Flow Cytometry and Automated Cell Counter in Mammalian and Microalgae Cells

  2018cites this paper
• Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers in vivo.

  2018cites this paper
• Loading and Controlled Releasing of Anti-cancer Drug Bortezomib by Glucose-Containing Diblock Copolymer

  2017cites this paper
• Cholic acid-based novel micellar nanoplatform for delivering FDA-approved taxanes.

  2017cites this paper
• Extremely long tumor retention, multi‐responsive boronate crosslinked micelles with superior therapeutic efficacy for ovarian cancer

  2017cites this paper
• A facile strategy for fine-tuning the stability and drug release of stimuli-responsive cross-linked micellar nanoparticles towards precision drug delivery.

  2017cites this paper
• Histone deacetylase inhibitor thailandepsin-A activates Notch signaling and suppresses neuroendocrine cancer cell growth in vivo

  2017cites this paper
• A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer

  2017cites this paper
• Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems.

  2016cites this paper
• KE108-conjugated unimolecular micelles loaded with a novel HDAC inhibitor thailandepsin-A for targeted neuroendocrine cancer therapy.

  2016cites this paper
• Epigenetic Mechanism in Breast Cancer

  2016cites this paper